Paper Details

  1. Home
  2. Paper Details

Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.

Author: AdedoyinA, AnaissieE, BernardoJ F, BolsackL E, BoyleA, BranchR A, DeValeriolaD, DeWitS, HorwithG, KellyE, KlasterksyJ, Llanos-CuentasA, Lopez-BeresteinG, SculierJ P, SwensonC E

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study examines the pharmacokinetics of ABELCET, a new formulation of amphotericin B (AmB), in various pharmacokinetic and efficacy studies. The data suggest that ABELCET exhibits a faster clearance and larger volume of distribution compared to conventional AmB formulations.
Paper Details　
Original Abstract of the Article :
Amphotericin B (AmB) has been the most effective systemic antifungal agent, but its use is limited by the dose-limiting toxicity of the conventional micellar dispersion formulation (Fungizone). New formulations with better and improved safety profiles are being developed and include ABELCET (formerl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1128/AAC.41.10.2201

データ提供：米国国立医学図書館（NLM）

ABELCET: A New Approach to Amphotericin B Treatment

The treatment of fungal infections is a complex and challenging field, like navigating a vast and unforgiving desert. This study, published in the field of

infectious diseases

, investigates the pharmacokinetic profile of ABELCET, a new lipid-based formulation of amphotericin B. The researchers explored the unique properties of ABELCET and how it compares to traditional amphotericin B formulations.

A Safer and More Effective Option

The study revealed that ABELCET exhibits a faster clearance and larger volume of distribution compared to traditional amphotericin B formulations, leading to lower blood concentrations and potentially a reduced risk of side effects. This is like finding a more efficient route through the desert, allowing for a more comfortable and effective journey. This new formulation could potentially improve the safety and efficacy of amphotericin B treatment.

A More Favorable Journey for Patients

This research offers a potential improvement in the treatment of fungal infections. ABELCET's unique pharmacokinetic profile could lead to a safer and more effective treatment experience for patients. It's like finding a smoother path through the desert, leading to a more comfortable and successful outcome for those facing fungal infections.

Dr. Camel's Conclusion

This study, like a caravan exploring a new path through a harsh desert, reveals the potential benefits of ABELCET, a new formulation of amphotericin B. The study suggests that ABELCET may be safer and more effective than traditional amphotericin B formulations, offering a potentially smoother journey for patients battling fungal infections. It's a reminder that even in the seemingly barren desert of fungal infection treatment, there can be hidden oases of hope and innovation.

Date :
  1. Date Completed 1997-11-24
  2. Date Revised 2020-07-24
Further Info :

Pubmed ID

9333048

DOI: Digital Object Identifier

10.1128/AAC.41.10.2201

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.